Recent

% | $
Quotes you view appear here for quick access.

Cyclacel Pharmaceuticals, Inc. Message Board

  • stockangel1@ymail.com stockangel1 Jan 21, 2013 9:41 PM Flag

    WoW that's all I can say ADXS about to help cure / treat cervical cancer! Phase 2 Trials in process!

    If your just looking to diversify a little of your gains from CYCC you might think about one of the hottest little start up bio stocks of 2013! Phase one trials were a complete success. Phase 2 trial results do out soon for the treatment or cure of cervical cancer! If this works the same science might be used to treat or cure many other forms of cancer in the human body! This is truly an exciting year for ADXS just two weeks ago the company hires a new VP and it's the former VP of ImClone this guy has the skills and inside connections to really boost the company he also lead to ImClones buyout buy major pharma in 2008!! Then just last month secured 11 million in non dilutive financing enough to last the rest of this year and into next unless of course they end up in a partnership or JV or get bought out this year!

    Check this one out add them to your list of stocks to watch I can promise you this it will be one exciting stock in 2013 and beyond!

    Peace to you and good luck with all your investments I hope they double and triple multiple times this year alone!

    Your personal Stock Angel

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • So they hired a former VP at Imclone? I gotta think Imclone had VP's like Mexico has Mexicans.. I don't see that as anything necessarily big. He was probably just as surprised as everyone else when Imclone got a BO...

      • 1 Reply to dndn_man
      • stockangel1@ymail.com stockangel1 Jan 22, 2013 6:53 PM Flag

        Thomas Moore, Advaxis’ Chairman and Chief Executive Officer, stated, “We are delighted to welcome Dan O’Connor to Advaxis. Now that our clinical development has reached an advanced stage, his success as a general counsel and in leading business development and licensing negotiations is a timely addition to our management team. We are very fortunate to attract a highly experienced professional of this caliber. It is a significant endorsement of Advaxis’ immunotherapy technology and our potential to unlock unrealized enterprise value.”

        Mr. O’Connor, age 48, has fifteen years of executive, legal, and regulatory experience in the biopharmaceutical industry with ImClone Systems, PharmaNet and Bracco Diagnostics.

        "I believe that Advaxis’ future holds tremendous potential," said Mr. O’Connor. "I look forward to continuing the company's culture of decisiveness and efficient execution. We will aggressively advance ADXS-HPV and our other pipeline product candidates, while building commercial alliances to both accelerate product development and generate shareholder value."

        Joining ImClone in 2003, Mr. O’Connor supported the clinical development, launch, and commercialization of ERBITUX(R). As ImClone’s senior vice president, general counsel, and secretary, he played a key role in resolving numerous issues facing ImClone, including extensive licensing negotiations, in advance of the company being sold to Eli Lilly in 2008.

        Just saying this doesn't really sound like he was surprised ImClone got bought out...

        Sentiment: Strong Buy

 
CYCC
5.14-0.13(-2.47%)Jun 24 4:00 PMEDT